PHVS Profile
Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare and underserved diseases. The company's primary focus is on creating treatments for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent and unpredictable episodes of severe swelling. Pharvaris is advancing a range of therapeutic candidates aimed at addressing this condition and improving patient outcomes.
Pharvaris's lead product, PHA121, is a small molecule bradykinin B2-receptor antagonist currently in Phase II clinical trials. This drug aims to offer a novel approach to managing HAE by targeting the bradykinin pathway, which plays a crucial role in the disease's pathology. Additionally, the company is developing PHVS416, an on-demand soft capsule designed for rapid relief during acute HAE attacks. This product is undergoing Phase II clinical trials to assess its efficacy and safety for patients in acute distress.
The company is also advancing PHVS719, a prophylactic extended-release tablet intended for long-term prevention of HAE attacks. This candidate is in Phase I clinical trials and represents a strategic component of Pharvaris's broader effort to provide sustained relief for individuals with HAE. By focusing on both acute and preventive treatment options, Pharvaris aims to address different aspects of disease management and improve the overall quality of life for patients.
Incorporated in 2015 and headquartered in Leiden, the Netherlands, Pharvaris operates across multiple regions including the Netherlands, Switzerland, and the United States. The company's strategic focus on rare diseases and its innovative pipeline reflect its commitment to addressing unmet medical needs and advancing therapeutic solutions. Pharvaris continues to build on its clinical and operational expertise as it works towards bringing its therapies to market and making a meaningful impact in the field of rare diseases.
|
